RAP-219 — Initial data
Q4 2026
Initial data from the long-term open-label extension of the Phase 2a trial are expected in the fourth quarter of 2026.Source filing
RAPP biotech catalysts & pipeline
RAPPORT THERAPEUTICS INC · Data as of 2026-10-25
Upcoming catalysts
RAP-219 — Topline data
H1 2027
Outside of FOS, Rapport is conducting a Phase 2 trial evaluating RAP-219 in bipolar mania, with topline results expected in the first half of 2027, and a Phase 3 trial in primary generalized tonic-clonic seizures is expected to begin in the first half of 2027.Source filing
RAP-219 — FDA meeting
Q1 2027
Rapport plans to meet with the U.S. Food and Drug Administration (FDA) in the first quarter of 2027 to discuss the Phase 2 data and registrational trial design for RAP-219 in bipolar mania.Source filing
RAP-219 — Clinical data readout
Q3 2027
Phase 1 pharmacokinetic (PK) data for an LAI formulation of RAP-219 are expected in the third quarter of 2027.Source filing
RAP-641 — Initial data
H2 2027
RAP-641: Phase 1 preliminary results are expected in the second half of 2027.Source filing